Recombinant Bispecific Antibodies Targeting TSLP and IL4R
Summary
USPTO published patent application US20260109758A1 on April 23, 2026, disclosing recombinant bispecific antibodies comprising a TSLP binding domain and an IL4R binding domain, invented by Mingjiu Chen, Mark Zhiqing Ma, and Zeyu Peng (Application No. 19114283, filed September 20, 2023). The disclosure covers nucleic acid molecules encoding the antibodies, vectors, host cells, production processes, medical uses, and kits comprising the recombinant bispecific antibodies. CPC classifications include C07K 16/244, C07K 16/2866, and therapeutic indicators A61P 11/06 and A61P 17/00.
“The present disclosure provides a recombinant bispecific antibody comprising i) a TSLP binding domain, and ii) an IL4R binding domain.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260109758A1 disclosing recombinant bispecific antibodies comprising both a TSLP (thymic stromal lymphopoietin) binding domain and an IL4R (interleukin-4 receptor) binding domain. The application covers the bispecific antibody construct, nucleic acid encoding, viral or expression vectors, host cells transformed with the vector, manufacturing processes, pharmaceutical compositions, medical/therapeutic uses, and kits containing the antibodies. CPC classifications indicate therapeutic applications in respiratory (A61P 11/06) and dermatological (A61P 17/00) conditions.
Pharmaceutical and biotechnology companies developing bispecific antibody therapeutics, particularly in the inflammation and allergy space, should monitor this application for potential freedom-to-operate considerations or licensing opportunities. The dual-targeting of TSLP and IL4R represents a combination approach for inflammatory diseases, which may overlap with existing programs targeting these pathways individually.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RECOMBINANT BISPECIFIC ANTIBODIES TARGETING TSLP AND IL4R
Application US20260109758A1 Kind: A1 Apr 23, 2026
Inventors
Mingjiu CHEN, Mark Zhiqing MA, Zeyu PENG
Abstract
The present disclosure provides a recombinant bispecific antibody comprising i) a TSLP binding domain, and ii) an IL4R binding domain. The present disclosure provides a nucleic acid molecule encoding the recombinant bispecific antibody, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector or with such a nucleic acid molecule. Furthermore, the present disclosure provides a process for the production of the recombinant bispecific antibody, a medical use of the recombinant bispecific antibody and a kit comprising the recombinant bispecific antibody.
CPC Classifications
C07K 16/244 A61P 11/06 A61P 17/00 C07K 16/2866 C07K 2317/24 C07K 2317/31 C07K 2317/622 C07K 2317/76 C07K 2317/92
Filing Date
2023-09-20
Application No.
19114283
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.